CoChat

Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans

Lemere, Cynthia A., Maier, Marcel, Jiang, Liying, Peng, Ying, Seabrook, Timothy J. · 2006 · Rejuvenation Research
Cited by 69

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Alzheimer disease (AD), the most common form of dementia, is without an effective cure or preventive treatment. Recently, amyloid-beta protein (A β ) has become a major therapeutic target. Many efforts are underway to either reduce the production of A β or enhance its clearance. In 1999, Schenk and colleagues first showed that active immunization with full-length A β lowered cerebral A β levels in transgenic mice. These findings have been confirmed and extended in various transgenic mouse models of AD using both active and passive A β immunization. Cognitive improvement also has been reported in association with active and passive A β vaccination in AD-like mouse models, even in the absence of significant reductions in cerebral A β loads. In 2004, the authors reported that active immunization with fulllength A β in aged nonhuman primates, Caribbean vervets, reduced cerebral A β levels and gliosis. Proposed mechanisms of A β clearance by immunotherapy include disruption of A β aggregates, A β phagocytosis by microglia, neutralization of A β oligomers at the synapse, and increased efflux of A β from brain to blood. A phase IIa clinical trial was halted in 2002 because of the appearance of meningoencephalitis in ∼6% of the AD patients. Although the exact cause of these adverse events is unknown, the immunogen, full-length A β 1-42, may have been recognized as a self-antigen leading to an autoimmune response in some patients. Limited cognitive stabilization and apparent plaque clearance have been reported in subsets of patients who generated antibody titers. Currently, a passive immunization trial with a recombinant humanized monoclonal A β antibody is underway in humans. In the meantime, the authors are developing novel A β peptide immunogens for active immunization to target A β B cell epitope(s) and avoid A β -specific T-cell reactions in order to generate a safe and effective AD vaccine. The authors remain optimistic about the potential of such a vaccine for the prevention and treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/rej.2006.9.77

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 69

Metadata

Authors
Lemere, C. A., Maier, M., Jiang, L., Peng, Y., & Seabrook, T. J.
Venue
Rejuvenation Research
Published
2006-03
Volume
9
Issue
1
Pages
77-84
ISSN
  • 1094-5458 (ISSN-L)
  • 1549-1684
  • 1557-8577
OpenAlex
W2014344489
Cited by
69
References
19
FWCI
4.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans. https://app.cochat.ai/papers/10.1089/rej.2006.9.77
The paper
Lemere, C. A., Maier, M., Jiang, L., Peng, Y., & Seabrook, T. J. (2006). Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans. Rejuvenation Research. https://doi.org/10.1089/rej.2006.9.77

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.